Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

  • NMRD releases fiscal Q2-2021 results, provides business update
  • Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board
  • Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector 

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286).

Financial highlights from the announcement included $26.8M cash on hand, and receipt of an initial $513,000 as deposit payment from its UK licensee as partial payment for an order of 200,000 sensors and associated devices. Management expects to convert this and future invoiced payments to revenue once the Company begins delivering the final product to its licensee, scheduled to start during Q4-2021. 

NMRD is currently commercializing its sugarBEAT(R) and proBEAT(TM) non-invasive and flexible continuous glucose monitors that provide actionable insights from real-time glucose monitoring to help diabetic and pre-diabetic people better manage, reverse, and prevent the onset of diabetes. The Company recently welcomed Dr. Osama Hamdy, M.D., Ph.D., to its advisory board, who will take part and advise on diabetes and metabolic health studies using Nemaura’s glucose monitoring technology. Dr. Hamdy is a senior endocrinologist and medical director, Obesity Clinic Program at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School. Dr. Hamdy is a world-renowned thought leader in the field of obesity management in diabetes, medical nutrition and digital health.

NMRD also announced the signing of a global commercial contract with MySugarWatch DuoPack Limited to provide continuous glucose monitors and sensors as Duo-Packs, to be sold with prescription-only medicines typically prescribed to people with Type 2 diabetes. “We continue to make progress in our commercializing efforts for sugarBEAT(R) in the UK and recognizing revenue from our licensee. We are also working closely with advisors to expand our footprint throughout the world to address the worldwide health crisis of diabetes using our skin-mounted needle-free CGM as an innovative solution for patients and consumers,” said Dr. Faz Chowdhury, CEO of Nemaura Medical. 

“Combined with our digital lifestyle management programs, we believe that our technology offering has the potential to be a key tool for the prevention and management of Type 2 diabetes. As we progress with our corporate, clinical, and regulatory milestones, we will provide future investor updates.”

Founded in 2011, Nemaura initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved with the creation of wearable technologies and digital health care solutions at the intersection of three rapidly growing markets: the global Type 2 diabetes market expected to reach $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable weight loss and wellness applications sector, estimated to reach $60 billion by 2023 (https://ibn.fm/0MG5U). With obesity and diabetes as the two major drivers fueling the chronic disease epidemic, NMRD is committed to preventing, managing, and reversing these conditions by offering non-invasive, affordable, and flexible glucose monitoring solutions. 

For more information, visit the company websites at www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050